News
JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target
19 Apr 24
News, Price Target, Reiteration, Analyst Ratings
JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target
18 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Vigil Presents Key Findings From ILLUMINATE & IGNITE Studies In ALSP At The 2024 American Academy Of Neurology Annual Meeting
17 Apr 24
Biotech, News, General
HC Wainwright & Co. Maintains Buy on Vigil Neuroscience, Maintains $24 Price Target
27 Mar 24
News, Price Target, Analyst Ratings
Vigil Neuroscience: Q4 Earnings Insights
26 Mar 24
Earnings
Vigil Neuroscience Q4 EPS $(0.57) Misses $(0.53) Estimate, Cash Balance of $117.9M
26 Mar 24
Earnings, News
Vigil Announces Oral Presentation On Small Molecule TREM2 Agonist VG-3927 As A Potential Disease-Modifying Therapeutic At AD/PD 2024
6 Mar 24
Biotech, News, General
Vigil Presents Poster On Impacts Of Misdiagnosis And Genetic Testing On Adult-Onset Leukoencephalopathy With Axonal Spheroids And Pigmented Glia Patient Journey At ACTRIMS 2024
29 Feb 24
Biotech, News, General
Press releases
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
17 Apr 24
Press Releases
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
26 Mar 24
Earnings, Press Releases
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
13 Mar 24
News, Health Care, Press Releases
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
12 Mar 24
News, Press Releases
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
6 Mar 24
News, Press Releases